18 June 2019
By Dr Wendy Winnall - PCFA Research Team
Enzalutamide (Xtandi) is a medicine that helps men with metastatic prostate cancer live longer. In Australia it's used by men with late-stage disease, called metastatic castration resistant prostate cancer. A large Australian and New Zealand clinical trial has now shown that Enzalutamide improves survival times if taken at an earlier stage, with hormone therapy. But unfortunately adding Enzalutamide to hormone therapy brings a higher risk of side effects.
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.
